Venus Remedies Limited has informed the Exchange regarding 'Adoption of MOA & AOA as per Companies Act 2013'.
VENUSREM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Venus Remedies reported strong FY2026 results with standalone net profit of Rs 99.31 crore, up 89% from Rs 52.55 crore in FY2025. Consolidated net profit rose 127% to Rs 102.78 crore. Revenue from operations grew 19% to Rs 768.73 crore standalone. The Board has recommended a final dividend of Rs 10 per share (100% on face value Rs 10), with record date August 7, 2026 and AGM on August 20, 2026. Key director changes include reappointment of Mr. Saransh Chaudhary as Managing Director and appointment of Dr. Gurminder Singh Bedi and Dr. Savita Gupta as Independent Directors for 5 years. New auditors appointed: C.L. Bansal & Associates (Cost) and Mehra Goel & Co (Internal) for FY2026-27. The company also adopted new MOA and AOA aligned with Companies Act 2013, replacing the old Act 1956 documents.
Strong profitability growth and shareholder-friendly dividend signal positive momentum. Director appointments bring fresh independent oversight. MOA/AOA adoption is routine compliance with no impact on operations.